SWOG clinical trial number
SWOG-8008

Evaluation of Dihydroxyanthracenedione (DHAD) in Refractory Breast Cancer

Closed
Phase
Abbreviated Title
Evaluation of Dihydroxyanthracenedione (DHAD) in Refractory Breast Cancer
Activated
07/02/1980
Closed
09/10/1982

Publication Information Expand/Collapse

1983

Mitoxantrone in advanced breast cancer: A Phase II trial of the Southwest Oncology Group

WA Knight;DD Von Hoff;JA Neidhart;BL Tranum;C Fabian;SE Jones Investigational New Drugs 1:181-184

Southwest Oncology Group Phase II studies with Mitoxantrone in nonhematologic malignancies.

RL Stephens;DD Von Hoff;SA Taylor;WA Knight III;RB Livingston;FE Bull;J Cowan;RD Hilgers;CK Osborne;GA Gates;G Clark In: New Anticancer Drugs: Mitoxantrone and Bisantrene . M Rozencweig, et al, eds. New York: Raven Press, 125-30

Cardiotoxicity in patients treated with Mitoxantrone on Southwest Oncology Group Phase II protocols.

GM Clark;LK Tokaz;DD Von Hoff;LL Thoi;CA Coltman Jr Cancer Treat Symp 3:25-30

1982

Phase II trial of dihydroxyanthracenedione (DHAD, Breast Mitoxantrone) in breast cancer: A Southwest Oncology Group study

WA Knight III;DD Von Hoff;B Tranum;R O'Bryan ASCO #C-335

1981

Southwest Oncology Group (SWOG) Phase II with mitoxantrone in non-hematologic malignancies.

RL Stephens;G Clark 3rd NCI-EORTC Symposium on New Drugs in Cancer Therapy (October 15-17, 1981), #36